ADCT Stock Summary and Trading Ideas (Adc Therapeutics SA Common Shares | NYSE:ADCT)

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.

Adc Therapeutics SA Common Shares trades on the NYSE stock market under the symbol ADCT.

As of November 7, 2024, ADCT stock price declined to $2.93 with 496,851 million shares trading.

ADCT has a beta of 2.40, meaning it tends to be more sensitive to market movements. ADCT has a correlation of 0.05 to the broad based SPY ETF.

ADCT has a market cap of $283.18 million. This is considered a Small Cap stock.

Last quarter Adc Therapeutics SA Common Shares reported $17 million in Revenue and -$.25 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.19.

In the last 3 years, ADCT traded as high as $29.74 and as low as $.36.

The top ETF exchange traded funds that ADCT belongs to (by Net Assets): IWM, IWO, VTWO, IWN, IWC.

ADCT has outperformed the market in the last year with a return of +304.0%, while the SPY ETF gained +37.9%. However, in the most recent history, ADCT shares have underperformed the stock market with its stock returning +6.9% in the last 3 month period and +1.4% for the last 2 week period, while SPY has returned +15.2% and +2.8%, respectively.

ADCT support price is $3.06 and resistance is $3.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADCT shares will trade within this expected range on the day.